Anticancer agent 311

Anticancer agent 311 是一种凋亡 (apoptosis) 诱导剂和 p53 调节剂,可提升 p53 水平、激活 cleaved caspase-3、降低 p-Cdc25C 水平并阻断 p-p44/42 MAPK 的磷酸化过程,从而诱导 G2/M 期停滞,以浓度和时间依赖性方式抑制癌细胞活力且对非癌细胞毒性较低,并在小鼠异种移植模型中抑制肿瘤生长和血管生成且未检测到毒性,因此可用于肺癌的研究。
产品编号: MS-F70726 CAS No.: 421579-95-5 分子式: C23H18FNO5S 分子量: 439.46
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Anticancer agent 311 是一种凋亡 (apoptosis) 诱导剂和 p53 调节剂,可提升 p53 水平、激活 cleaved caspase-3、降低 p-Cdc25C 水平并阻断 p-p44/42 MAPK 的磷酸化过程,从而诱导 G2/M 期停滞,以浓度和时间依赖性方式抑制癌细胞活力且对非癌细胞毒性较低,并在小鼠异种移植模型中抑制肿瘤生长和血管生成且未检测到毒性,因此可用于肺癌的研究。

生物实验数据

生物活性 Anticancer agent 311 is an apoptosis inducer and p53 modulator that elevates p53 levels, activates cleaved caspase-3, decreases p-Cdc25C levels, and blocks the phosphorylation of p-p44/42 MAPK, thereby inducing G2/M phase arrest, inhibiting cancer cell viability in a concentration- and time-dependent manner with low toxicity to non-cancer cells, and suppressing tumor growth and angiogenesis in mouse xenograft models without detectable toxicity, making it applicable for lung cancer research.
IC50 & Target

Caspase-3

 

体外研究
(In Vitro)

Anticancer agent 311 (#2714) (48 小时) 能有效抑制小鼠 Lewis 肺癌 LL/2 细胞的活力,IC50 为 5.43 μM,抑制小鼠乳腺癌 4T1 细胞的活力,IC50 为 6.12 μM,同时对非癌性 NIH-3T3 和 HK-2 细胞的毒性极低 (IC50 >40 μM)。
Anticancer agent 311 (4-20 μM;24-72 小时) 以时间和浓度依赖的方式抑制 LL/2 细胞活力。
Anticancer agent 311 (5-20 μM;48 小时) 可诱导小鼠 Lewis 肺癌 LL/2 细胞发生 G2/M 期阻滞,20 μM 组有 77.7%的细胞停滞于 G2/M 期。
Anticancer agent 311 (5-20 μM;48 小时) 可呈浓度依赖性诱导小鼠 Lewis 肺癌 LL/2 细胞发生凋亡,在 20 μM 作用 48 小时后凋亡率达 50.2%,并会破坏这些细胞的线粒体膜电位。
Anticancer agent 311 (2.5-10 μM;24 小时) 在处理小鼠 Lewis 肺癌 LL/2 细胞 24 小时后,可下调 p-Cdc25C、p-p44/42 MAPK 和 p-Akt,同时上调 p53 和剪切型 caspase-3,这支持其诱导细胞发生 G2/M 期阻滞和 caspase 依赖的细胞凋亡。

Cell Viability Assay

Cell Line: Lewis lung carcinoma LL/2 cells
Concentration: 4 μM; 8 μM; 12 μM; 16 μM; 20 μM;
Incubation Time: 24 h; 48 h; 72 h
Result: Inhibited LL/2 cell viability in a time- and concentration-dependent manner.

Cell Cycle Analysis

Cell Line: Lewis lung carcinoma LL/2 cells
Concentration: 5 μM; 10 μM; 20 μM
Incubation Time: 48 h
Result: Increased the percentage of LL/2 cells in the G2/M phase to 77.7% at 20 μM, accompanied by decreases in the G0/G1 and S phases.

Apoptosis Analysis

Cell Line: Lewis lung carcinoma LL/2 cells
Concentration: 5 μM, 10 μM, 20 μM
Incubation Time: 48 h
Result: Increased the apoptosis rate of LL/2 cells to 22.9% with 5 μM, 45.1% with 10 μM, and 50.2% with 20 μM after 48 h.
Caused a concentration-dependent decrease in Rho 123 fluorescence, indicating collapse of mitochondrial membrane potential (ΔΨm).

Western Blot Analysis

Cell Line: Lewis lung carcinoma LL/2 cells
Concentration: 2.5 μM, 5 μM, 10 μM
Incubation Time: 24 h
Result: Downregulated the expression of phosphorylated Cdc25C (p-Cdc25C), phosphorylated p44/42 MAPK (p-p44/42 MAPK), and phosphorylated Akt (p-Akt) in a concentration-dependent manner.
Upregulated the expression of p53 and cleaved caspase-3 in a concentration-dependent manner.
体内研究
(In Vivo)

Anticancer agent 311 (#2714) (25-100 mg/kg;腹腔注射;每日一次;连续 14 天) 在健康 C57BL/6 小鼠中耐受性良好,每日给药剂量高达 100 mg/kg、连续给药 14 天仍未检测到毒性。
Anticancer agent 311 (#2714) (25-100 mg/kg;腹腔注射;每日一次;持续 28 天) 在 C57BL/6 小鼠中展现出强效抗肺癌活性,在 100 mg/kg 剂量下肿瘤生长抑制率最高可达 58.1%,同时还能延长生存期、减少血管生成并诱导肿瘤细胞凋亡,且未检测到毒性。

Animal Model: C57BL/6 (male and female, 18-22 g)
Dosage: 25 mg/kg; 50 mg/kg; 100 mg/kg
Administration: i.p.; daily; 14 days
Result: Caused no mortality, adverse clinical signs, or obvious pathological damage in any treated group.
Showed no significant differences in hematological parameters (WBC, RBC, HGB, HCT, PLT) between treated groups and vehicle control.
Showed no significant differences in serum biochemical parameters (HDL, TG, CHOL, CREA, BUN, GLU, ALP, ALB, TP, AST, ALT) between treated groups and vehicle control.
Animal Model: C57BL/6 (female, 6-8 weeks old, 18-22 g, subcutaneous implantation of LL/2 murine Lewis lung carcinoma cells)
Dosage: 25 mg/kg; 50 mg/kg; 100 mg/kg
Administration: i.p.; daily; 28 days
Result: Achieved 45.1% tumor growth inhibition at 50 mg/kg compared to vehicle control.
Achieved 58.1% tumor growth inhibition at 100 mg/kg compared to vehicle control.
Significantly increased mouse survival compared to vehicle control across all doses.
Reduced CD31 staining by 37.4% in tumor tissues compared to vehicle control.
Reduced CD105 staining by 15.2% in tumor tissues compared to vehicle control.
Increased apoptotic tumor cells 11-fold compared to vehicle control.
Caused no significant changes in body weight during treatment.

化学信息

分子量 439.46
分子式 C23H18FNO5S
CAS No. 421579-95-5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础